Piershale Financial Group’s AbbVie ABBV Stock Holding History

Piershale Financial Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$131K	Buy	971 +4	+0.4%	+$587	0.08%	21
2023 Q1	$154K	Buy	967 +5	+0.5%	+$764	0.12%	14
2022 Q4	$155K	Buy	+962	New	+$148K	0.13%	13
2016 Q4	–	Sell	-403	Closed	-$25K	–	25
2016 Q3	$25K	Sell	403 -129	-24%	-$8.35K	0.02%	55
2016 Q2	$33K	Buy	532 +136	+34%	+$8.29K	0.02%	42
2016 Q1	$23K	Sell	396 -72	-15%	-$4.01K	0.01%	53
2015 Q4	$28K	Buy	468 +78	+20%	+$4.49K	0.02%	58
2015 Q3	$21K	Sell	390 -3,998	-91%	-$260K	0.02%	53
2015 Q2	$295K	Sell	4,388 -390	-8%	-$25.5K	0.22%	12
2015 Q1	$280K	Buy	4,778 +24	+0.5%	+$1.45K	0.22%	12
2014 Q4	$311K	Buy	4,754 +2	+0%	+$126	0.2%	24
2014 Q3	$274K	Buy	4,752 +2	+0%	+$111	0.22%	28
2014 Q2	$268K	Sell	4,750 -70	-1%	-$3.67K	0.22%	27
2014 Q1	$248K	Sell	4,820 -36	-0.7%	-$1.82K	0.29%	29
2013 Q4	$256K	Buy	4,856 +3	+0.1%	+$147	0.37%	19
2013 Q3	$217K	Buy	4,853 +142	+3%	+$6.29K	0.2%	24
2013 Q2	$195K	Buy	+4,711	New	+$206K	0.38%	18

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piershale Financial Group's ABBV Position: Q2 2023 in Review

Piershale Financial Group increased its AbbVie (ABBV) stake by 0.41% in Q2 2023, buying an estimated $587 and bringing the position to 971 shares worth $131K. The position accounts for 0.08% of the portfolio, ranked #21.

Piershale Financial Group first reported a position in ABBV in Q2 2013 and has held it in 17 quarters since. The position peaked at $311K in Q4 2014. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

Piershale Financial Group held 971 shares of AbbVie worth $131K as of Q2 2023.
Piershale Financial Group bought 4 AbbVie shares in Q2 2023, an estimated $587.
AbbVie made up 0.08% of Piershale Financial Group's portfolio in Q2 2023, its #21 holding.
Piershale Financial Group first reported a position in AbbVie in Q2 2013 and has held it in 17 quarters since.
Piershale Financial Group's AbbVie position peaked at $311K in Q4 2014.
3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.